SCHEMBL4776514

SCHEMBL4776514

NC(C=O)C(c1ccc(Cl)cc1Cl)N1CCN(Cc2ccncc2F)CC1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.36
GPR6 P46095 4/20 0.35
SUV39H2 Q9H5I1 1/20 0.35
CYP3A4 P08684 5/20 0.35
CYP3A5 P20815 5/20 0.35
CYP2A13 Q16696 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CACNA2D1 P54289 1/20 0.33
CACNA1B Q00975 1/20 0.33
CACNB1 Q02641 1/20 0.33
CACNA1C Q13936 1/20 0.33
GPR183 P32249 1/20 0.33
SOS1 Q07889 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773088 0.84 SIGMAR1 (0.36) SIGMAR1CYP2A13KDM4EALDH1A1POLB
SCHEMBL4775561 0.81 MAPT (0.43) SIGMAR1
SCHEMBL4778381 0.78 LSS (0.40) SIGMAR1CYP3A4CYP3A5
SCHEMBL4778352 0.77 ALDH1A1 (0.40) SIGMAR1CYP3A4KDM4EALDH1A1POLB
SCHEMBL4776397 0.74 CYP3A4 (0.52) SIGMAR1CYP3A4KDM4EALDH1A1
SCHEMBL4776511 0.73 HDAC8 (0.53)
SCHEMBL4773571 0.72 CNR1 (0.48) CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL4772508 0.70 CYP3A4 (0.36) CYP3A4CYP3A5CACNA2D1CACNA1BCACNB1
SCHEMBL4778576 0.70 FAAH (0.47) KDM4EALDH1A1TDP1
SCHEMBL4771297 0.68 NPSR1 (0.46) KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed